Research Paper Volume 11, Issue 24 pp 12532—12545

Protease-activated receptor 2 (PAR-2) antagonist AZ3451 as a novel therapeutic agent for osteoarthritis

class="figure-viewer-img"

Figure 6. AZ3451 attenuates the activation of the P38/MAPK, NF-κB and PI3K/AKT/mTOR pathways induced by IL-1β in chondrocytes. (A, B) Representative western blots and quantification data of MAPK pathways in chondrocytes as treated above. (C, D) Representative western blots and quantification data of collagen II and aggrecan as treated above. (E, F) Representative western blots and quantification data of PI3K/AKT/mTOR pathways as treated above. (G, H) Representative western blots and quantification data of collagen II and aggrecan as treated above. (I, J) Representative western blots and quantification data of NF-κB pathways as treated above. (K, L) Representative western blots and quantification data of collagen II and aggrecan as treated above. (M, N) Representative western blots and quantification data of cytoplasmic P65 and nuclear P65 as treated above. (O) Immunofluorescence staining of the translocation of P65 in nuclear as treated above. Data are shown as the mean ± SD. Significant differences between groups are indicated as ***P <0.001, **P < 0.01 and *P < 0.05.